A study of AZD2962, an IRAK4 inhibitor (IRAK4 [a body protein] blocker), in Participants with Haematologic Neoplasms (Blood cancers)

Exclusion Criteria

• 1. Prior treatment with IRAK inhibitors or inhibitors of the inflammasome pathway.
• 2. Received any antineoplastic therapy (except hydroxyurea) within 15 days prior to first dose.
• 3. Received any strong or moderate Cytochrome P450 3A (CYP3A) inhibitors within 15 days prior to first dose.
• 4. Received major surgery within 28 days prior to first dose, or still recovering from surgery.
• 5. Received drugs that are known to prolong corrected QT interval (QTc) and with known risk of Torsades de Pointes, within 15 days prior to first dose.
• 6. Received immunosuppressive medications (including Graft-Versus-Host Disease prophylaxis) within 28 days prior to first dose, or within 15 days in the case of systemic steroids (doses exceeding 10 mg/day of prednisone or equivalent).
• 7. Received live attenuated vaccines within 28 days prior to first dose.
• 8. Active major bleeding event.
• 9. Any evidence of systemic disease, significant clinical disorder, or laboratory finding that make undesirable the participation in the study.
• 15. Mean resting corrected QT interval using Fridericia’s formula (QTcF) > 450 ms obtained from triplicate Electrocardiograms (ECGs) and averaged, recorded within 5 minutes. In the presence of bundle branch block, QTcF > 470 ms is applicable.
• 16. History of intracranial bleeding within 6 months prior to first dose.
• 17. Active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism or excretion of oral therapy.
• 18. History of a prior non-haematologic neoplasm (with some exceptions).
• 19. Unresolved Grade > 2 toxicities from prior anticancer therapies (with some exceptions).
• 20. Concurrent enrolment in another clinical study (with some exceptions).
• 21. Known hypersensitivity to study intervention or its excipients.